For more information or confidential assistance
800-306-3180
se habla español

Early Trials Selected for Growing Androgel Lawsuits

Eight Androgel lawsuits have been selected out of around 5,500 cases currently pending to serve as bellwether trials in the coordinated litigation. The bellwether trials are carefully selected to provide insight into how juries might respond to evidence and testimony in future trials. These early trials also can serve as... Read more »

New Study Highlights Nexium Dangers

Recent large scale epidemiological and retrospective studies have demonstrated links between the use of proton pump inhibitors (PPIs) and an increased risk of renal failure, myocardial infarction and dementia. On top of this, medical experts say that up to 70 percent of patients that take PPIs for treatment of heartburn... Read more »

Government Office Expresses Concern With FDA Drug Oversight

The federal Food and Drug Administration (FDA) is tasked with the tremendous responsibility of keeping American consumers safe from dangerous drugs and medical devices. Accordingly, the agency has not only implemented strict pre-market testing and screening measures for new products, but it is required to monitor the products after their... Read more »

New Report Warns of 21st Century Cures Act Shortfalls

drugreporter.com
In December 2015, non-profit group Public Citizen published a report highlighting a provision in the proposed 21st Century Cures Act that could cost taxpayers $12 billion — and that’s just one of the expenses. The report — written by Sammy Almashat and Sarah Sorscher of Public Citizen’s Health Research Group... Read more »

New Class of Diabetes Drugs Subject of FDA Warning

Less than two weeks ago, the FDA released an important drug safety communication regarding a new class of diabetes drugs, including those marketed under the brand names Invokana, Farxiga and Jardiance. Health regulators caution that diabetic patients taking this class of sodium-glucose cotransporter-2 (SGLT2) inhibitors may be at risk for... Read more »